Jefferies raised the firm’s price target on Novartis to $123 from $119 and keeps a Buy rating on the shares. Into Q4 earnings for European pharma, the firm is most comfortable with Novartis and GSK as the firm’s estimates are above consensus. Jefferies says the 2024 outlook could suggest consensus upside for Novartis.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVS:
- Cytokinetics extends decline, down 26% after WSJ said Novartis back away
- Novartis backing away from pursuit of Cytokinetics, WSJ reports
- Cytokinetics sinks 23% after WSJ says Novartis backed away from takeover
- M & A News: CYTK Stock Drops, Novartis Deal Hopes Diminish
- Cytokinetics slips after Novartis CEO says M&A focus on ‘bolt ons’
